Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2025/12/098644
CTRI/2025/12/098644RecruitingNot Applicable

Efficacy and safety of tirzepatide – a twincretin on weight and metabolic parameters in patients of Obesity with and without Diabetes mellitus

Dr Shruti chandra2 sites in 1 country78 target enrollmentStarted: December 16, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
78
Locations
2
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The study evaluates the efficacy and safety of tirzepatide, a dual GIP and GLP 1 receptor agonist, in patients of obesity with and without type 2 diabetes. Obesity is highly prevalent in India and contributes to major metabolic diseases. The prospective, open-label, interventional trial includes 78 participants assessing changes in weight, BMI, waist circumference, glycemic parameters, lipid profile, liver enzymes, and insulin resistance over 12 months. Participants will receive weekly tirzepatide injections with follow-up at 6 and 12 months. The study aims to generate population-specific evidence to support personalized obesity management and improve metabolic outcomes in Indian patients.

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
Female

Inclusion Criteria

  • •Patient of either gender between ages group 18 to 65 years Individual with BMI more than 25 kg per m square Patient is willing to participate in the study and give written informed consent Patient with or without type 2 DM.

Exclusion Criteria

  • •Patient having thyroid dysfunction Patients taking concurrent medications known to cause weight gain or weight loss Patient has a history of UTI and recurrent genitourinary infection Patient having renal and hepatic impairment Patient showing intolerance to tirzepatide Pregnant and Lactating women.

Investigators

Sponsor
Dr Shruti chandra
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr Shruti Chandra

MGM Medical College & Hospital

Study Sites (2)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, ParaguayOverweight With ComorbiditiesType 2 Diabetes MellitusObesity
NCT07492563LABORATORIOS INDUFAR300
Not yet recruiting
Unknown
To assess safety and effectiveness of Sitagliptin, Glimepiride, and Metformin for diabetes patients in India.
CTRI/2024/03/064004Torrent Pharmaceuticals Ltd7,000
Completed
Not Applicable
Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients
NCT07382180Azienda Sanitaria Locale Napoli 2 Nord254
Recruiting
Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)Obesity
NCT07481747Hudson Biotech2,539
Recruiting
Phase 4
A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS)
2024-515982-32-00Rheinische Friedrich-Wilhelms-Universitaet Bonn198